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What is happening inside the tuberculous granuloma? In this issue of Immunity, Egen et al. (2008) present live
images of tuberculous granulomas of the mouse, demonstrating the influx and incessant wandering of
T lymphocytes.Ilya Metchnikov published his observa-
tions of macrophages in action 116 years
ago, 10yearsafterRobertKochhadestab-
lished Mycobacterium tuberculosis (Mtb)
as the causative agent of tuberculosis
(TB). These findings have since become
linked by the appreciation that mycobac-
teria are inveterate macrophage patho-
gens, having evolved to circumvent and
even exploit these key immune effector
cells (Clay et al., 2007). Direct observation
of immune cells in action has since be-
come far more detailed, thanks to the in-
vention of new microscope technology
and the software necessary to explore im-
agedata in threeandeven four dimensions
(Bajenoff and Germain, 2007). During the
same time frame, tuberculosis has been
under more or less continuous study, but
despite advances in antibiotic therapy, re-
mains as intractable a global health prob-
lem as ever with the advent of increasingly
drug-resistant Mtb strains. Setting aside
the obvious public health, social, and eco-
nomic failures to control TB, its continued
status as the ‘‘Captain of all Men of Death’’
stems from the inexplicable persistence
of Mtb in the face of an apparently solid
immune response and vaccination with
Mycobacterium bovis Bacillus Calmette-
Gue´rin (BCG), the world’s most widely
used yet relatively ineffective vaccine. An
emerging body of work utilizing the power
of in vivo imaging tocrack the secretsof TB
has begun to shed light on the arguable
center of the mystery: the granuloma (Da-
vis et al., 2002; Volkman et al., 2004). The
study in this issue of Immunity by Egen
et al. (2008) extends these earlier studies
to offer insights into the granuloma after
adaptive immunity has come into play.
What then are granulomas? These
complex organized immunological struc-146 Immunity 28, February 2008 ª2008 Elsevtures are comprised of differentiated, in-
terdigitated macrophages (the so-called
epithelioid cells) that are subsequently
joined by other immune cells such as T
and B lymphocytes and NK cells (Adams,
1976). Granulomas form in humans in re-
sponse to a variety of persistent stimuli,
be they pathogens (e.g., Mycobacteria
and Brucella) or foreign bodies, as well
as in certain mystery diseases such as
sarcoidosis. Tuberculosis is by far the
most prevalent cause of human granulo-
mas world-wide, such that the patholo-
gist’s finding of granulomas promptly
sets off a search for signs of tuberculosis.
Tuberculous infection is initiated in hu-
mans by airborne Mtb within cough drop-
lets that gain access to the deepest alveoli
of a victim’s lungs, where the bacterium is
phagocytosed by alveolar macrophages
and dendritic cells (Dannenberg, 1993).
Frequently failing to kill their new cargo,
these cells serve as effective transporters
of the bacteria from the airway into deeper
tissues (Clay et al., 2007), where they
soon aggregate into granulomas. Live im-
aging studies in the transparent develop-
ing zebrafish infected with Mycobacte-
rium marinum, a close genetic relative of
Mtb, have shown that granulomas can
form as a result of mycobacterial interac-
tions with innate immunity alone (Davis
et al., 2002). Adaptive immune elements
then come into play but mysteriously
even the resultant bolstered response
can fail to eradicate these organisms, sug-
gesting that mycobacteria may counter or
even usurp a full range of host defenses
(Flynn, 2006; Cosma et al., 2004). For
years it has been thought that tuberculous
granulomas, like foreign body granulo-
mas, at least serve as an encircling barrier
to ‘‘wall off’’ material that cannot beier Inc.destroyed—a view that this study along
with other recent ones shows is simplistic
(Cosma et al., 2004; Egen et al., 2008;
Volkman et al., 2004).
Granuloma formation and maintenance
is an area ripe for in vivo imaging studies.
First, it is not clear exactly how infected
macrophages give rise to granulomas.
The initial inoculum of Mtb can be ex-
ceedingly small, perhaps even fewer
than 10 organisms, so that infection of
a single macrophage might well be suffi-
cient to establish infection. How would
single macrophages so lightly infected
give rise to granulomas that contain hun-
dreds of immune cells and many more
bacteria? Do single infected macro-
phages simply attract more macrophages
to achieve a critical mass of infectable
cells? What induces these infected mac-
rophages to become ‘‘granulomagenic’’?
Themycobacterial RD1 secretion system,
a virulence determinant, is required to in-
duce granuloma formation, but the mode
(e.g., cell migration, infection, or adhe-
sion) and mechanism are not clear (Volk-
man et al., 2004). Moreover, the source
of new macrophages (local versus sys-
temic, tissue versus blood-borne) is not
clear. The picture becomes increasingly
murky as the granuloma matures and
other immune cell types appear in the
granuloma. When and in what numbers
do they appear? Is their order and number
critical to the maturation of the lesion, or
to the outcome of infection? Are granulo-
mas permanent structures, or do they
come and go in different locations during
the years in which the average infected
human is thought to harbor infection? Fi-
nally, which, if any, of these steps are sus-
ceptible to intervention? Visual evidence,
and especially live, time-lapsed evidence,
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The transparent zebrafish embryo has
provided new insights into the early innate
immune phases of macrophage migration
and granuloma formation (Clay et al.,
2007; Davis et al., 2002; Volkman et al.,
2004). For the adaptive immune phase of
granuloma formation, however, the
mouse with its plentiful immunological re-
agents and strains has distinct advan-
tages as a model organism. In an impres-
sive technical display, Egen et al. (2008)
have used the mouse to produce the first
live images of mycobacterial infection in
a mammalian host. Although the lung is
generally the subject of study in the
mousemodel of tuberculosis, its constant
movement, practically a condition for
physiologic normalcy, makes it unsuitable
for time-lapsed imaging under the micro-
scope. To overcome this problem, these
authors used intravenous infection to
initiate granulomas in the liver. Also, Mtb
work requires dedicated biosafety level 3
(BSL3) facilities, so these authors have
resorted to using a large inoculum of the
attenuated BCG vaccine strain (requiring
only BSL2 containment) to produce a per-
sistent infection with granulomas numer-
ous enough to be found under the micro-
scope without difficulty.
In a series of intricately clever manipu-
lations of transgenic mice and 3D time-
lapsemicroscopy, Egen et al. (2008) dem-
onstrate that blood-borne BCG is rapidly
taken up by Kupffer cells, the resident
macrophages of the liver (Figure 1). Both
the infected cells and the invading bacte-
ria appear to survive well over time, andafter several days, aggregates consist-
ing of the original infected Kupffer cells,
recruited Kupffer cells, andmonocyte-de-
rived macrophages are visible. These
myeloid cells are not very motile, although
their membranes do appear to be in con-
stant flux. The precise details of this
phase must be interpreted with caution,
because BCG is attenuated and lacks
the RD1 determinant that has been found
to enhance macrophage aggregation into
granulomas (Volkman et al., 2004). Con-
sistent with its attenuation, there is little
or no net bacterial growth in the first
3 weeks of infection, a period when path-
ogenic mycobacteria grow logarithmically
in their hosts, exemplified by Mtb in mice
(Flynn, 2006).
To probe granuloma dynamics further,
the authors blocked tumor necrosis fac-
tor-a (TNF-a) in established granulomas,
and within 4 days found smaller lesions
with reduced macrophage numbers. Im-
munofluorescence histology reveals that
TNF-ablockadedoes not alter the number
of infectedmacrophages in the lesion. The
selective loss of uninfected macrophages
has several possible explanations: the
treatment could lead to a reduced migra-
tion of new uninfected macrophages to
the lesion, or could differentially affect
the retention or survival of infected versus
uninfected macrophages. These possible
mechanisms and their effects on patho-
genesis can be explored further with this
and other in vivo models.
It is the movement and behavior of
T lymphocytes in granulomas that provide
the most intriguing findings of this study.
These cells, which arrive at the granulo-Immunitymas within days (Figure 1), are in constant
motion throughout the lesion. Theirmotion
is such that each lymphocyte appears
to wander through the entire granuloma,
likely making direct contact with most
of its macrophages. This finding begs
the question of how antigen-specific
T lymphocytes would behave. Would
they make more prolonged contacts with
macrophages expressing the relevant
antigen? The mechanics of the interaction
between arriving T cells and the macro-
phage matrix are of particular interest.
Activated T lymphocytes readily enter
lesions but they appear restrained from
leaving so that they accumulate therein.
Egen et al. (2008) propose that this reten-
tion of T cells is due to the macrophages
acting as a scaffold upon which the lym-
phocytes crawl, rather than to a physical
barrier to departure (Figure 1). This model
is similar to that proposed by this same
group forTcellsmigratingwithin lymphno-
des (Bajenoff and Germain, 2007). It has
been suggested that the granuloma may
serve as a form of tertiary lymphoid organ
(Ulrichs et al., 2004), and these new data
add to that discussion. After TNF block-
ade, T lymphocytes are still found in gran-
ulomas in reduced numbers. This reduc-
tion may be due to the overall reduction
ingranulomasizeafter anti-TNF treatment.
The emerging picture of the granuloma
as a tight accumulation of macrophages
that serves to support T cell migration
and contact—with infected cells, with
each other, with some unseen cell type—
is a revealing one indeed. Observations
of early, innate immune granuloma forma-
tion have suggested a highly dynamicFigure 1. Stages of BCG Granuloma Formation in the Mouse Liver
Upon infection, blood-borne bacteria are phagocytosed by resident Kupffer cells. At 2 weeks after infection, infected Kupffer cells have attracted local resident
macrophages and monocyte-derived macrophages. Arriving T lymphocytes are also seen. By 3 weeks after infection, T cells are plentiful among the macro-
phages. T cells migrate in constant contact with a ‘‘scaffold’’ of macrophages.28, February 2008 ª2008 Elsevier Inc. 147
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(Davis et al., 2002). Egen et al. (2008) sim-
ilarly find an adaptive immune-stage gran-
uloma in constant motion. The ultimate
contribution of all this motion and action
to pathogenesis will be known only after
further study; however, this report adds
convincingly to the argument that the
granuloma cannot be thought of as simply
a barricade to contain mycobacteria,
even after adaptive immunity is estab-
lished.148 Immunity 28, February 2008 ª2008 ElsevREFERENCES
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